SMALL ANIMAL MODELS OF LENTIVIRUS INFECTION FOR EVALUATING HIVTHERAPEUTICS



NIH GUIDE, Volume 23, Number 33, September 16, 1994



RFP AVAILABLE:  NIH-NIAID-DAIDS-95-17



P.T.





Keywords:



National Institute of Allergy and Infectious Diseases



The Developmental Therapeutics Branch, Basic Research and Development

Program, Division of AIDS, NIAID, NIH, has a requirement for the

evaluation of antiviral therapies/strategies for HIV-1/AIDS in

established small animal models of lentivirus infection.  These

capabilities will be used by the Division of AIDS, NIAID, it its effort

to develop antiviral therapies/strategies for human subjects infected

with HIV-1.  Evaluation encompasses in vitro and in vivo determinations

of efficacy and toxicity, and when needed, limited pharmacokinetics for

in vivo studies.  Further characterization and modification of the

proposed animal model, or development of other models may be required.

Therapies to be tested, alone and in combination, include antiviral

agents (drugs and biologics), gene-based and other novel strategies.

Examples of lentivirus models considered at this time to be appropriate

for this RFP include HIV-1 in immunocompromised mice constituted with

human cells or tissues and feline immunodeficiency virus in cats;

nonhuman primate models are excluded from the competition.



This announcement is for the recompetition of several current animal

model contracts.  The RFP is now available and proposals will be due by

COB on or about November 30, 1994.  It is anticipated that two level-

of-effort, cost-reimbursement type contracts will be awarded and that

the period of performance for each contract will be four years

(estimated start date August 1, 1995).  The Government reserves the

right to make only one award per animal model and to limit the number

of awards based on the merit of the technical proposals received.  It

is estimated that the Contractor will expend 340 percent effort per

year in accomplishment of the Government's objectives for this

requirement.



INQUIRIES



A short-form version of the RFP will be available, for informational

purposes, which includes only the background information, the full

Statement of Work, and Evaluation Criteria.  There is sufficient

information in this document to enable prospective offerors to

determine if they have the expertise/capability to meet the

Government's requirements.  A full-text version will also be available,

which includes all the necessary information, business forms, etc., in

order to submit a proposal.  There are a limited number of full-text

versions available.  Therefore, request the short-form RFP first, then

the full-text version only if you are going to submit a proposal.  All

requests must be in writing.  Specify if you are requesting the short-

version or full-text version of the RFP.  FAX requests are acceptable,

but written requests containing two self-addressed mailing labels are

preferred.



Requests for the RFP must be directed to:



Mr. Bruce E. Anderson

Contract Management Branch

National Institute of Allergy and Infectious Diseases

Solar Building, Room 3C07

6003 Executive Boulevard

Bethesda, MD  20892-7610

Telephone:  (301) 496-8371

FAX:  (301) 402-0972



.

Return to 1994 Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.